BioNTech’s mRNA cancer vaccine misses Phase 2/3 endpoint
BioNTech’s BNT113, combined with Keytruda, failed to significantly improve progression-free survival in a Phase 2/3 head and neck cancer trial. The study will continue to assess whether the combination helps patients live longer.
Why it matters: mRNA cancer immunotherapies are a central part of BioNTech’s oncology strategy. The result raises the pressure to demonstrate clinical benefit, although the ongoing trial could still succeed through its second primary endpoint: overall survival.
Zoom in: AHEAD-MERIT is testing BNT113 plus the PD-1 checkpoint inhibitor pembrolizumab (Keytruda) against pembrolizumab alone as a first-line treatment for unresectable, recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma expressing PD-L1.
- The combination did not significantly improve progression-free survival, which measures time until the cancer worsens or the patient dies. An independent monitoring committee recommended continuing the trial to evaluate overall survival. Under the prespecified statistical design, a significant survival benefit would establish a positive trial outcome despite the missed endpoint.
How it works: BNT113 is an off-the-shelf vaccine whose mRNA encodes the HPV16 proteins E6 and E7. These viral oncoproteins provide targets for a T-cell response against cancer cells, which the checkpoint inhibitor is intended to strengthen.
There is precedent: Missing progression-free survival does not necessarily rule out a later overall survival benefit. Two immunotherapy trials illustrate that possibility:
- KEYNOTE-048: Pembrolizumab improved overall survival in head and neck cancer despite missing its progression-free survival endpoint. FDA approval came in June 2019, and the drug is now a standard treatment.
- CheckMate-648: Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved overall survival in esophageal squamous cell carcinoma without significantly improving progression-free survival. FDA approval came in May 2022.
These examples leave room for a positive outcome, but they do not predict BNT113’s remaining result.
The big picture: BioNTech’s mRNA oncology strategy extends beyond BNT113, with both fixed-antigen and individualized approaches:
- BNT111: Encodes a fixed selection of tumor-associated antigens and was tested with cemiplimab in advanced melanoma. Its Phase 2 trial met the primary objective response rate endpoint in 2024, but the comparison relied on a historical control group.
- BNT116: Targets several antigens found in non-small cell lung cancer and is being tested with cemiplimab in Phase 2.
- Autogene cevumeran (BNT122): An individualized neoantigen therapy tested in several cancers through BioNTech’s collaboration with Genentech. A colorectal cancer trial was terminated in August 2026 after an independent committee issued a negative benefit-risk assessment.
What’s next: The overall survival analysis will determine whether BNT113 can still demonstrate a benefit that makes AHEAD-MERIT positive. Until then, the missed endpoint remains a significant setback.
